Statistics for Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema
Total visits
| views | |
|---|---|
| Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema | 6 |
Total visits per month
| views | |
|---|---|
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
File Visits
| views | |
|---|---|
| main.pdf | 12 |
Top country views
| views | |
|---|---|
| India | 4 |
| United States | 2 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |
| Hyderabad | 1 |
| Mumbai | 1 |